The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
// Ramiro Vázquez 1 , María E. Riveiro 2 , Lucile Astorgues-Xerri 2 , Elodie Odore 2, 3 , Keyvan Rezai 3 , Eugenio Erba 1 , Nicolò Panini 1 , Andrea Rinaldi 4 , Ivo Kwee 4, 5, 6 , Luca Beltrame 1 , Mohamed Bekradda 2 , Esteban Cvitkovic 2, 7 , Francesco Bertoni 4, 8 , Roberta Frapolli 1 , Maurizio D'Incalci 1 1 Laboratory of Anti-tumor Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy 2 Oncology Therapeutic Development, Clichy, France 3 Radiop
OpenAlex
3523d ago
Agents & autonomyBiotech